Buy PEG-MGF Research Peptide

What is PEG-MGF?

PEG-MGF is a longer-lasting form of MGF, with PEG chains attached so it stays active for hours instead of minutes. This lets researchers study more sustained MGF signaling and its effects on muscle repair cells in animal research.

• A PEG-attached form of Mechano Growth Factor with a longer active life
• PEG extends its active time from minutes to hours in studies
• Keeps MGF’s effects on muscle repair cells in research models
• Studied in animal research on muscle responses to injury and stress

For research use only. Not approved for human therapeutic use.

PEG-MGF (PEGylated Mechano Growth Factor) is a synthetically modified 24-amino acid peptide derived from the IGF-1 Ec splice variant, covalently conjugated to a polyethylene glycol (PEG) moiety. The core peptide corresponds to the C-terminal E-domain of Mechano Growth Factor, with an approximate molecular weight of 4500 g/mol inclusive of the PEG chain. PEGylation is a well-established chemical modification strategy employed to alter the physicochemical characteristics of the native peptide, including its susceptibility to enzymatic degradation. Produced via solid-phase peptide synthesis with subsequent PEG conjugation, PEG-MGF is associated with IGF-1 receptor-mediated signalling pathways in preclinical research.

PEGylated Mechano Growth Factor has been extensively investigated in preclinical cell biology and tissue physiology research, with particular focus on satellite cell populations and their role in skeletal muscle adaptation. In vitro studies in C2C12 myoblast cell lines have examined the compound’s interaction with the IGF-1R, characterising differential contributions of the Ec E-peptide to myoblast proliferation and differentiation relative to mature IGF-1, with downstream signalling activity documented across MAPK/ERK-mediated mitogenic pathways [1]. In vivo studies have explored the pharmacokinetic implications of PEGylation on MGF, comparing circulating half-life and tissue distribution profiles between PEG-conjugated and non-conjugated forms. Rodent cardiovascular models have also examined the E-domain peptide’s interaction with cardiac tissue, with published work documenting MGF E-peptide activity in rat cardiomyocyte preparations and in infarcted myocardium in vivo [2], an area that has made PEG-MGF a key subject of preclinical investigation beyond the skeletal muscle axis.

PEG-MGF is produced to research-grade standards and independently verified by third-party HPLC and MS-UPLC analysis before dispatch. Vials are vacuum sealed and stored in a temperature controlled, monitored cold storage system. Certificates of Analysis are available on request.

Sold strictly for in vitro research purposes only. Not for human consumption. Intended for use by qualified researchers in laboratory settings only.

References

1Yang SY, Goldspink G. Different roles of the IGF-I Ec peptide (MGF) and mature IGF-I in myoblast proliferation and differentiation. FEBS Lett. 2002 Jul 3;522(1–3):156–60. .PubMed PMID: 120956372Stavropoulou A, Halapas A, Sourla A, Philippou A, Papageorgiou E, Papalois A, et al. IGF-1 expression in infarcted myocardium and MGF E peptide actions in rat cardiomyocytes in vitro. Mol Med. 2009;15(5–6):127–35. ; PubMed Central PMCID: PMC2656994.PubMed PMID: 19295919

Scientific Review

Dr. Martina Rossi, PhD

Scientific Contributor and Reviewer

Reviewed for scientific accuracy, 14 June 2026

View credentials →

PEG-MGF (PEGylated Mechano Growth Factor) is a synthetically modified 24-amino acid peptide derived from the IGF-1 Ec splice variant, covalently conjugated to a polyethylene glycol (PEG) moiety. The core peptide corresponds to the C-terminal E-domain of Mechano Growth Factor, with an approximate molecular weight of 4500 g/mol inclusive of the PEG chain. PEGylation is a well-established chemical modification strategy employed to alter the physicochemical characteristics of the native peptide, including its susceptibility to enzymatic degradation. Produced via solid-phase peptide synthesis with subsequent PEG conjugation, PEG-MGF is associated with IGF-1 receptor-mediated signalling pathways in preclinical research.

PEGylated Mechano Growth Factor has been extensively investigated in preclinical cell biology and tissue physiology research, with particular focus on satellite cell populations and their role in skeletal muscle adaptation. In vitro studies in C2C12 myoblast cell lines have examined the compound’s interaction with the IGF-1R, characterising differential contributions of the Ec E-peptide to myoblast proliferation and differentiation relative to mature IGF-1, with downstream signalling activity documented across MAPK/ERK-mediated mitogenic pathways [1]. In vivo studies have explored the pharmacokinetic implications of PEGylation on MGF, comparing circulating half-life and tissue distribution profiles between PEG-conjugated and non-conjugated forms. Rodent cardiovascular models have also examined the E-domain peptide’s interaction with cardiac tissue, with published work documenting MGF E-peptide activity in rat cardiomyocyte preparations and in infarcted myocardium in vivo [2], an area that has made PEG-MGF a key subject of preclinical investigation beyond the skeletal muscle axis.

PEG-MGF is produced to research-grade standards and independently verified by third-party HPLC and MS-UPLC analysis before dispatch. Vials are vacuum sealed and stored in a temperature controlled, monitored cold storage system. Certificates of Analysis are available on request.

Sold strictly for in vitro research purposes only. Not for human consumption. Intended for use by qualified researchers in laboratory settings only.

References

1Yang SY, Goldspink G. Different roles of the IGF-I Ec peptide (MGF) and mature IGF-I in myoblast proliferation and differentiation. FEBS Lett. 2002 Jul 3;522(1–3):156–60. .PubMed PMID: 120956372Stavropoulou A, Halapas A, Sourla A, Philippou A, Papageorgiou E, Papalois A, et al. IGF-1 expression in infarcted myocardium and MGF E peptide actions in rat cardiomyocytes in vitro. Mol Med. 2009;15(5–6):127–35. ; PubMed Central PMCID: PMC2656994.PubMed PMID: 19295919

Scientific Review

Dr. Martina Rossi, PhD

Scientific Contributor and Reviewer

Reviewed for scientific accuracy, 14 June 2026

View credentials →CAS NumberN/A (PEGylated conjugate)Molecular Weight~4,000–5,000 g/mol (variable PEG chain)Purity≥98%Physical FormLyophilised PowderManufacturingManufactured in an ISO9001 Certified LaboratoryTestingHPLC + MS-UPLCSKUPEGMGF

Lyophilised powder: store at -20 °C or below, away from light and moisture. Once reconstituted in an appropriate laboratory diluent (e.g. sterile water, PBS, or assay buffer), store at 2–8 °C and use within the validated period for your protocol. Do not refreeze.

PEG-MGF (PEGylated Mechano Growth Factor) is a synthetically modified 24-amino acid peptide derived from the IGF-1 Ec splice variant, covalently conjugated to a polyethylene glycol (PEG) moiety. The core peptide corresponds to the C-terminal E-domain of Mechano Growth Factor, with an approximate molecular weight of 4500 g/mol inclusive of the PEG chain. PEGylation is a well-established chemical modification strategy employed to alter the physicochemical characteristics of the native peptide, including its susceptibility to enzymatic degradation. Produced via solid-phase peptide synthesis with subsequent PEG conjugation, PEG-MGF is associated with IGF-1 receptor-mediated signalling pathways in preclinical research.

PEGylated Mechano Growth Factor has been extensively investigated in preclinical cell biology and tissue physiology research, with particular focus on satellite cell populations and their role in skeletal muscle adaptation. In vitro studies in C2C12 myoblast cell lines have examined the compound’s interaction with the IGF-1R, characterising differential contributions of the Ec E-peptide to myoblast proliferation and differentiation relative to mature IGF-1, with downstream signalling activity documented across MAPK/ERK-mediated mitogenic pathways [1]. In vivo studies have explored the pharmacokinetic implications of PEGylation on MGF, comparing circulating half-life and tissue distribution profiles between PEG-conjugated and non-conjugated forms. Rodent cardiovascular models have also examined the E-domain peptide’s interaction with cardiac tissue, with published work documenting MGF E-peptide activity in rat cardiomyocyte preparations and in infarcted myocardium in vivo [2], an area that has made PEG-MGF a key subject of preclinical investigation beyond the skeletal muscle axis.

PEG-MGF is produced to research-grade standards and independently verified by third-party HPLC and MS-UPLC analysis before dispatch. Vials are vacuum sealed and stored in a temperature controlled, monitored cold storage system. Certificates of Analysis are available on request.

Sold strictly for in vitro research purposes only. Not for human consumption. Intended for use by qualified researchers in laboratory settings only.

References

1Yang SY, Goldspink G. Different roles of the IGF-I Ec peptide (MGF) and mature IGF-I in myoblast proliferation and differentiation. FEBS Lett. 2002 Jul 3;522(1–3):156–60. .PubMed PMID: 120956372Stavropoulou A, Halapas A, Sourla A, Philippou A, Papageorgiou E, Papalois A, et al. IGF-1 expression in infarcted myocardium and MGF E peptide actions in rat cardiomyocytes in vitro. Mol Med. 2009;15(5–6):127–35. ; PubMed Central PMCID: PMC2656994.PubMed PMID: 19295919

Scientific Review

Dr. Martina Rossi, PhD

Scientific Contributor and Reviewer

Reviewed for scientific accuracy, 14 June 2026

View credentials →CAS NumberN/A (PEGylated conjugate)Molecular Weight~4,000–5,000 g/mol (variable PEG chain)Purity≥98%Physical FormLyophilised PowderManufacturingManufactured in an ISO9001 Certified LaboratoryTestingHPLC + MS-UPLCSKUPEGMGF

Lyophilised powder: store at -20 °C or below, away from light and moisture. Once reconstituted in an appropriate laboratory diluent (e.g. sterile water, PBS, or assay buffer), store at 2–8 °C and use within the validated period for your protocol. Do not refreeze.